Cargando…

The Oral β-Lactamase SYN-004 (Ribaxamase) Degrades Ceftriaxone Excreted into the Intestine in Phase 2a Clinical Studies

SYN-004 (ribaxamase) is a β-lactamase designed to be orally administered concurrently with intravenous β-lactam antibiotics, including most penicillins and cephalosporins. Ribaxamase's anticipated mechanism of action is to degrade excess β-lactam antibiotic that is excreted into the small intes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kokai-Kun, John F., Roberts, Tracey, Coughlin, Olivia, Sicard, Eric, Rufiange, Marianne, Fedorak, Richard, Carter, Christian, Adams, Marijke H., Longstreth, James, Whalen, Heidi, Sliman, Joseph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2017
Materias:	Experimental Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5328510/ https://www.ncbi.nlm.nih.gov/pubmed/28052855 http://dx.doi.org/10.1128/AAC.02197-16

Ejemplares similares

SYN-004 (ribaxamase) prevents New Onset Clostridium difficile Infection by Protecting the Integrity Gut Microbiome in a Phase 2b Study
por: Kokai-Kun, John, et al.
Publicado: (2017)

1337. SYN-004 (Ribaxamase) Protects the Gut Microbiome of Patients Treated With Ceftriaxone From Disruption and Reduces the Emergence of Antimicrobial Resistance
por: Kokai-Kun, John, et al.
Publicado: (2018)

Ribaxamase, an Orally Administered β-Lactamase, Diminishes Changes to Acquired Antimicrobial Resistance of the Gut Resistome in Patients Treated with Ceftriaxone
por: Kokai-Kun, John F, et al.
Publicado: (2020)

270 SYN-004, a Class A Beta-Lactamase Therapy for the Prevention of Antibiotic-Induced Disruption of Intestinal Microflora
por: Kaleko, Michael, et al.
Publicado: (2014)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

Cyclic Boronates Inhibit All Classes of β-Lactamases
por: Cahill, Samuel T., et al.
Publicado: (2017)

The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant Enterobacterales
por: Lomovskaya, Olga, et al.
Publicado: (2022)

Microbiological Characterization of VNRX-5236, a Broad-Spectrum β-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum β-Lactamases and Serine Carbapenemases
por: Chatwin, Cassandra L., et al.
Publicado: (2021)

Safety and Pharmacokinetic Characterization of Nacubactam, a Novel β-Lactamase Inhibitor, Alone and in Combination with Meropenem, in Healthy Volunteers
por: Mallalieu, Navita L., et al.
Publicado: (2020)

In vitro efficacy of humanized regimen of flomoxef against extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
por: Yamashiro, Hidenori, et al.
Publicado: (2023)

Resistance of Undisturbed Soil Microbiomes to Ceftriaxone Indicates Extended Spectrum β-Lactamase Activity
por: Gatica, Joao, et al.
Publicado: (2015)

Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii
por: Sakoulas, George, et al.
Publicado: (2017)

ZN148 Is a Modular Synthetic Metallo-β-Lactamase Inhibitor That Reverses Carbapenem Resistance in Gram-Negative Pathogens In Vivo
por: Samuelsen, Ørjan, et al.
Publicado: (2020)

VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
por: Hamrick, Jodie C., et al.
Publicado: (2020)

SYST-18 BELZUTIFAN TREATMENT FOR PATIENTS WITH VON HIPPEL-LINDAU DISEASE–ASSOCIATED CENTRAL NERVOUS SYSTEM HEMANGIOBLASTOMAS ENROLLED IN THE PHASE 2 LITESPARK-004 STUDY
por: Narayan, Vivek, et al.
Publicado: (2023)

Patisiran Pharmacokinetics, Pharmacodynamics, and Exposure‐Response Analyses in the Phase 3 APOLLO Trial in Patients With Hereditary Transthyretin‐Mediated (hATTR) Amyloidosis
por: Zhang, Xiaoping, et al.
Publicado: (2019)

Cystatins 9 and C as a Novel Immunotherapy Treatment That Protects against Multidrug-Resistant New Delhi Metallo-Beta-Lactamase-1-Producing Klebsiella pneumoniae
por: Holloway, Alex J., et al.
Publicado: (2018)

Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-β-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018–2020 Global Surveillance Collection
por: Karlowsky, James A., et al.
Publicado: (2022)

Pharmacodynamics of Finafloxacin, Ciprofloxacin, and Levofloxacin in Serum and Urine against TEM- and SHV-Type Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae Isolates from Patients with Urinary Tract Infections
por: Dalhoff, A., et al.
Publicado: (2017)

Seasons of Syn
por: Hunter‐Cevera, Kristen R., et al.
Publicado: (2019)

Generation of three human induced pluripotent stem cell sublines (UCLAi004-A, UCLAi004-B, and UCLAi004-C) for reproductive science research
por: Pandolfi, Erica C., et al.
Publicado: (2021)

Antiamoebic Properties of Ceftriaxone and Zinc-Oxide–Cyclodextrin-Conjugated Ceftriaxone
por: Makhlouf, Zinb, et al.
Publicado: (2022)

OR10-004 - Circulating micrornas in TRAPS
por: Lucherini, OM, et al.
Publicado: (2013)

OR7-004 – Validation of AIDAI score
por: Piram, M, et al.
Publicado: (2013)

Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model
por: Posma, Rene A, et al.
Publicado: (2020)

Impact of ceftriaxone and temocillin on fecal abundance of extended-spectrum β-lactamase producing Escherichia coli in a mouse model
por: Chenouard, Rachel, et al.
Publicado: (2021)

Effect of Intensive Glycemic and Blood Pressure Control on QT Prolongation in Diabetes: The ACCORD Trial
por: Singleton, Matthew J., et al.
Publicado: (2020)

Ceftriaxone-induced hemolysis
por: Guleria, Vivek S., et al.
Publicado: (2013)

Ceftriaxone‐associated pseudolithiasis
por: Kurihara, Masaru, et al.
Publicado: (2021)

P01-004 – MEFV genes and FMF
por: Salehzadeh, F, et al.
Publicado: (2013)

AB004. Peyronie’s disease: 2017 update
por: Lue, Tom F.
Publicado: (2017)

Detection and Mitigation of SYN Flooding Attacks through SYN/ACK Packets and Black/White Lists
por: Yang, Chun-Hao, et al.
Publicado: (2023)

Critical appraisal of adverse effects reporting in the ‘Treatment for Adolescents With Depression Study (TADS)’
por: Westergren, Tone, et al.
Publicado: (2019)

Adverse effects information in clinical guidelines on pharmacological treatment of depression in children and adolescents: a systematic review
por: Westergren, Tone, et al.
Publicado: (2020)

Adherence to statin or aspirin or both in patients with established cardiovascular disease: exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome
por: Wei, Li, et al.
Publicado: (2008)

Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease
por: Germain, Dominique P, et al.
Publicado: (2015)

Rescue of primary ubiquinone deficiency due to a novel COQ7 defect using 2,4–dihydroxybensoic acid
por: Freyer, Christoph, et al.
Publicado: (2015)

Prescriptions and Dispensing
Publicado: (1908)

Prescriptions and Dispensing
Publicado: (1908)

Natural Mineral Waters
Publicado: (1908)

Cannot write session to /tmp/vufind_sessions/sess_g2bdomjrq9u41vev84j0v67k2b